Saro H Armenian

List of Publications by Year
in descending order

142 papers	7,023 citations	61984 43 h-index	64796 79 g-index
153 all docs	153 docs citations	153 times ranked	7130 citing authors

#	Article	IF	Citations
1	Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2017, 35, 893-911.	1.6	860
2	Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncology, The, 2015, 16, e123-e136.	10.7	453
3	Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. Journal of Clinical Oncology, 2016, 34, 1122-1130.	1.6	376
4	A worldwide collaboration to harmonize guidelines for the longâ€term followâ€up of childhood and young adult cancer survivors: A report from the international late effects of Childhood Cancer Guideline Harmonization Group. Pediatric Blood and Cancer, 2013, 60, 543-549.	1.5	275
5	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. European Heart Journal, 2022, 43, 280-299.	2.2	213
6	Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). Blood, 2011, 118, 1413-1420.	1.4	176
7	Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease. Blood, 2012, 120, 4505-4512.	1.4	168
8	Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report. Biology of Blood and Marrow Transplantation, 2016, 22, 782-795.	2.0	155
9	Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Childrenâ€™s Oncology Group Randomized Trial Pediatric Oncology Group 9404. Journal of Clinical Oncology, 2016, 34, 854-862.	1.6	154
10	Biology of premature ageing in survivors of cancer. ESMO Open, 2017, 2, e000250.	4.5	148
11	Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention. Journal of Clinical Oncology, 2018, 36, 2135-2144.	1.6	139
12	Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood, 2011, 118, 6023-6029.	1.4	136
13	Cardiovascular Disease Risk Profiles in Survivors of Adolescent and Young Adult (AYA) Cancer: The Kaiser Permanente AYA Cancer Survivors Study. Journal of Clinical Oncology, 2016, 34, 1626-1633.	1.6	133
14	Late Congestive Heart Failure After Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2008, 26, 5537-5543.	1.6	125
15	Hyaluronan Synthase 3 Variant and Anthracycline-Related Cardiomyopathy: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2014, 32, 647-653.	1.6	122
16	Association of Exercise With Mortality in Adult Survivors of Childhood Cancer. JAMA Oncology, 2018, 4, 1352.	7.1	103
17	CELF4 Variant and Anthracycline-Related Cardiomyopathy: A Childrenâ€™s Oncology Group Genome-Wide Association Study. Journal of Clinical Oncology, 2016, 34, 863-870.	1.6	102
18	Burden of Morbidity in 10+ Year Survivors of Hematopoietic Cell Transplantation: Report from the Bone Marrow Transplantation Survivor Study. Biology of Blood and Marrow Transplantation, 2013, 19, 1073-1080.	2.0	101

#	Article	IF	Citations
19	Cost-Effectiveness of the Children's Oncology Group Long-Term Follow-up Screening Guidelines for Childhood Cancer Survivors at Risk for Treatment-Related Heart Failure. Annals of Internal Medicine, 2014, 160, 672.	3.9	100
20	Chronic Comorbidities Among Survivors of Adolescent and Young Adult Cancer. Journal of Clinical Oncology, 2020, 38, 3161-3174.	1.6	95
21	Genetic susceptibility to anthracyclineâ€related congestive heart failure in survivors of haematopoietic cell transplantation. British Journal of Haematology, 2013, 163, 205-213.	2.5	94
22	Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction. Journal of the American Heart Association, 2020, 9, e014708.	3.7	94
23	Physiologic Frailty in Nonelderly Hematopoietic Cell Transplantation Patients. JAMA Oncology, 2016, 2, 1277.	7.1	93
24	Yield of Screening for Long-Term Complications Using the Children's Oncology Group Long-Term Follow-Up Guidelines. Journal of Clinical Oncology, 2012, 30, 4401-4408.	1.6	92
25	Predictors of Late Cardiovascular Complications inÂSurvivors of Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 1138-1144.	2.0	85
26	Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary. Journal of Oncology Practice, 2017, 13, 270-275.	2.5	85
27	Predicting and Preventing Anthracycline-Related Cardiotoxicity. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 3-12.	3.8	84
28	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report. Biology of Blood and Marrow Transplantation, 2017, 23, 201-210.	2.0	79
29	Collaborative Research in Childhood Cancer Survivorship: The Current Landscape. Journal of Clinical Oncology, 2015, 33, 3055-3064.	1.6	77
30	Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment. Cardiovascular Research, 2019, 115, 922-934.	3.8	77
31	National Cancer Instituteâ€“National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on Late Effects After Pediatric Hematopoietic Cell Transplantation: Long-Term Organ Damage and Dysfunction. Biology of Blood and Marrow Transplantation, 2011, 17, 1573-1584.	2.0	76
32	Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2015, 33, 2639-2645.	1.6	76
33	Children's Oncology Group's 2013 blueprint for research: Survivorship and outcomes. Pediatric Blood and Cancer, 2013, 60, 1063-1068.	1.5	65
34	NCCN Guidelines Insights: Survivorship, Version 2.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 784-794.	4.9	65
35	Cardiovascular disease in survivors of hematopoietic cell transplantation. Cancer, 2014, 120, 469-479.	4.1	64
36	NCCN Guidelines Insights: Survivorship, Version 2.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1016-1023.	4.9	64

#	Article	IF	Citations
37	Screening for Cardiac Dysfunction in Anthracycline-Exposed Childhood Cancer Survivors. Clinical Cancer Research, 2014, 20, 6314-6323.	7.0	61
38	Premature Aging in Young Cancer Survivors. Journal of the National Cancer Institute, 2019, 111, 226-232.	6.3	61
39	Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. Blood Advances, 2018, 2, 1756-1764.	5.2	53
40	Long-Term Pulmonary Function in Survivors of Childhood Cancer. Journal of Clinical Oncology, 2015, 33, 1592-1600.	1.6	52
41	How I monitor long-term and late effects after blood or marrow transplantation. Blood, 2017, 130, 1302-1314.	1.4	52
42	Impact of Sarcopenia on Adverse Outcomes After Allogeneic Hematopoietic Cell Transplantation. Journal of the National Cancer Institute, 2019, 111, 837-844.	6.3	46
43	Response-adapted anti-PD-1â€“based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood, 2022, 139, 3605-3616.	1.4	46
44	Childhood cancer survivorship. Current Opinion in Pediatrics, 2013, 25, 16-22.	2.0	45
45	Cardiovascular disease after hematopoietic cell transplantation - lessons learned. Haematologica, 2008, 93, 1132-1136.	3.5	44
46	Prospective Monitoring for Invasive Aspergillosis Using Galactomannan and Polymerase Chain Reaction in High Risk Pediatric Patients. Journal of Pediatric Hematology/Oncology, 2009, 31, 920-926.	0.6	43
47	Cardiovascular disease following hematopoietic stem cell transplantation: Pathogenesis, detection, and the cardioprotective role of aerobic training. Critical Reviews in Oncology/Hematology, 2016, 98, 222-234.	4.4	38
48	Risk Factors for Mortality Resulting From Bloodstream Infections in a Pediatric Intensive Care Unit. Pediatric Infectious Disease Journal, 2005, 24, 309-314.	2.0	36
49	Counseling and surveillance of obstetrical risks for female childhood, adolescent, and young adultÂcancerÂsurvivors: recommendations fromÂtheÂInternationalÂLate Effects of Childhood CancerÂGuidelineÂHarmonization Group. American Journal of Obstetrics and Gynecology, 2021, 224, 3-15.	1.3	35
50	Management of retinoblastoma with proximal optic nerve enhancement on MRI at diagnosis. Pediatric Blood and Cancer, 2008, 51, 479-484.	1.5	33
51	Trends in Late Mortality and Life Expectancy After Allogeneic Blood or Marrow Transplantation Over 4 Decades. JAMA Oncology, 2021, 7, 1626.	7.1	33
52	Rationale and design of the Childrenâ€™s Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure. BMC Cardiovascular Disorders, 2016, 16, 187.	1.7	32
53	SAFETY AND IMMUNOGENICITY OF LIVE VARICELLA VIRUS VACCINE IN CHILDREN WITH HUMAN IMMUNODEFICIENCY VIRUS TYPE 1. Pediatric Infectious Disease Journal, 2006, 25, 368-370.	2.0	31
54	Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group. Cancer, 2022, 128, 788-796.	4.1	29

#	Article	IF	Citations
55	Sex-Specific Cardiovascular Risks of Cancer and Its Therapies. Circulation Research, 2022, 130, 632-651.	4.5	29
56	Optimizing Cardiovascular Care in Children With Acute Myeloid Leukemia to Improve Cancer-Related Outcomes. Journal of Clinical Oncology, 2019, 37, 1-6.	1.6	28
57	Cardiovascular Function in Long-Term Hematopoietic Cell Transplantation Survivors. Biology of Blood and Marrow Transplantation, 2017, 23, 700-705.	2.0	27
58	Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood. JAMA Oncology, 2018, 4, e182453.	7.1	27
59	Physiologic Frailty Among Hematopoietic Cell Transplantation (HCT) Survivors Suggests Accelerated Aging and Is a Predictor for Premature Mortality: A Report from the Bone Marrow Transplant Survivor Study (BMTSS). Blood, 2015, 126, 739-739.	1.4	26
60	Guidance regarding COVIDâ€19 for survivors of childhood, adolescent, and young adult cancer: A statement from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Pediatric Blood and Cancer, 2020, 67, e28702.	1.5	25
61	Cost-Effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group Screening Guidelines to Prevent Heart Failure in Survivors of Childhood Cancer. Journal of Clinical Oncology, 2020, 38, 3851-3862.	1.6	25
62	Longitudinal Changes in Echocardiographic Parameters ofÂCardiacÂFunction in Pediatric Cancer Survivors. JACC: CardioOncology, 2020, 2, 26-37.	4.0	24
63	Causeâ€specific mortality in survivors of adolescent and young adult cancer. Cancer, 2020, 126, 2305-2316.	4.1	24
64	Strategies to Prevent Anthracycline-Related Congestive Heart Failure in Survivors of Childhood Cancer. Cardiology Research and Practice, 2012, 2012, 1-8.	1.1	23
65	Evaluation of persistent pulmonary infiltrates in pediatric oncology patients. Pediatric Blood and Cancer, 2007, 48, 165-172.	1.5	22
66	Chronic Health Conditions in Childhood Cancer Survivors: Is it All Treatment-Relatedâ€”or Do Genetics Play a Role?. Journal of General Internal Medicine, 2009, 24, 395-400.	2.6	20
67	Accuracy of a Novel Handheld Wireless Platform for Detection of Cardiac Dysfunction in Anthracycline-Exposed Survivors of Childhood Cancer. Clinical Cancer Research, 2018, 24, 3119-3125.	7.0	20
68	Conditional Survival, Cause-Specific Mortality, and Risk Factors of Late Mortality After Allogeneic Hematopoietic Cell Transplantation. Journal of the National Cancer Institute, 2020, 112, 1153-1161.	6.3	20
69	Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2517-2521.	2.0	19
70	Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantation. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 962-972.	7.3	19
71	Carnitine and Cardiac Dysfunction in Childhood Cancer Survivors Treated with Anthracyclines. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1109-1114.	2.5	17
72	The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity. JACC: CardioOncology, 2019, 1, 105-113.	4.0	17

#	Article	IF	Citations
73	Feasibility of a behavioral intervention using mobile health applications to reduce cardiovascular risk factors in cancer survivors: a pilot randomized controlled trial. Journal of Cancer Survivorship, 2021, 15, 554-563.	2.9	17
74	Atrial Fibrillation in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2021, 39, 902-910.	1.6	15
75	Prevalence of anthracyclineâ€related cardiac dysfunction in longâ€term survivors of adultâ€onset lymphoma. Cancer, 2018, 124, 850-857.	4.1	14
76	Cardiovascular Health during and after Cancer Therapy. Cancers, 2020, 12, 3737.	3.7	14
77	Approaches to Reduce the Long-Term Burden of Treatment-Related Complications in Survivors of Childhood Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 196-204.	3.8	13
78	Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center. Biology of Blood and Marrow Transplantation, 2020, 26, 292-299.	2.0	13
79	Feasibility and Acceptability of Using a Telehealth Platform to Monitor Cardiovascular Risk Factors in Hematopoietic Cell Transplantation Survivors at Risk for Cardiovascular Disease. Biology of Blood and Marrow Transplantation, 2020, 26, 1233-1237.	2.0	13
80	Secondary Neoplasms of the Female Lower Genital Tract After Hematopoietic Cell Transplantation. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 211-218.	4.9	12
81	A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at Risk for Breast Cancer. Clinical Cancer Research, 2021, 27, 967-974.	7.0	12
82	Trends in Late Mortality and Life Expectancy After Autologous Blood or Marrow Transplantation Over Three Decades: A BMTSS Report. Journal of Clinical Oncology, 2022, 40, 1991-2003.	1.6	11
83	Invasive diagnostic procedures for pulmonary infiltrates in pediatric hematopoietic stem cell transplant recipients. Pediatric Transplantation, 2007, 11, 736-742.	1.0	10
84	Cardiac Dysfunction and Heart Failure in Hematopoietic Cell Transplantation Survivors. Heart Failure Clinics, 2017, 13, 337-345.	2.1	10
85	Late mortality after autologous blood or marrow transplantation in childhood: a Blood or Marrow Transplant Survivor Study-2 report. Blood, 2018, 131, 2720-2729.	1.4	10
86	Dexrazoxane preferentially mitigates doxorubicin cardiotoxicity in female children with sarcoma. Open Heart, 2019, 6, e001025.	2.3	10
87	Detailed phenotyping reveals distinct trajectories of cardiovascular function and symptoms with exposure to modern breast cancer therapy. Cancer, 2019, 125, 2762-2771.	4.1	10
88	Late-occurring venous thromboembolism in allogeneic blood or marrow transplant survivors: a BMTSS-HiGHS2 risk model. Blood Advances, 2021, 5, 4102-4111.	5.2	10
89	Optimization of Health and Extension of Lifespan Through Childhood Cancer Survivorship Research. Journal of Clinical Oncology, 2018, 36, 2133-2134.	1.6	9
90	Venous Thromboembolism in Autologous Blood or Marrow Transplantation Survivors: A Report from the Blood or Marrow Transplant Survivor Study. Biology of Blood and Marrow Transplantation, 2019, 25, 2261-2266.	2.0	9

#	Article	IF	Citations
91	Risk of venous thromboembolism in patients with nonâ€Hodgkin lymphoma surviving blood or marrow transplantation. Cancer, 2019, 125, 4498-4508.	4.1	9
92	Late Mortality after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism: A Report from the Blood or Marrow Transplant Survivor Study-2 (BMTSS-2). Biology of Blood and Marrow Transplantation, 2019, 25, 328-334.	2.0	9
93	Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT. Blood, 2015, 126, 519-519.	1.4	9
94	Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1105-1123.	4.9	9
95	Cardiometabolic Risk in Childhood Cancer Survivors: A Report from the Children's Oncology Group. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 536-542.	2.5	9
96	Cardiovascular events in cancer survivors. Seminars in Oncology, 2019, 46, 426-432.	2.2	8
97	Cardiomyopathy in Childhood Cancer Survivors: Lessons from the Past and Challenges for the Future. Current Oncology Reports, 2016, 18, 22.	4.0	7
98	Morbidity burden in survivors of multiple myeloma who underwent autologous transplantation: A Bone Marrow Transplantation Survivor Study. Cancer, 2020, 126, 3322-3329.	4.1	7
99	Pain in older survivors of hematologic malignancies after blood or marrow transplantation: A BMTSS report. Cancer, 2020, 126, 2003-2012.	4.1	7
100	Longitudinal trajectory of frailty in blood or marrow transplant survivors: Report from the Blood or Marrow Transplant Survivor Study. Cancer, 2021, 127, 794-800.	4.1	7
101	Integration of Pediatric Hodgkin Lymphoma Treatment and Late Effects Guidelines: Seeing the Forest Beyond the Trees. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 755-764.	4.9	7
102	Burden of Long-Term Morbidity Borne by Survivors of Acute Myeloid Leukemia Treated With Blood or Marrow Transplantation: The Results of the BMT Survivor Study. Journal of Clinical Oncology, 0, , .	1.6	7
103	Late mortality in blood or marrow transplant survivors with venous thromboembolism: report from the Blood or Marrow Transplant Survivor Study. British Journal of Haematology, 2019, 186, 367-370.	2.5	6
104	Lateâ€occurring infections in a contemporary cohort of hematopoietic cell transplantation survivors. Cancer Medicine, 2021, 10, 2956-2966.	2.8	6
105	Efficacy of low-dose zoster prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2020, 55, 1662-1664.	2.4	5
106	Challenges associated with retrospective analysis of left ventricular function using clinical echocardiograms from a multicenter research study. Echocardiography, 2021, 38, 296-303.	0.9	5
107	Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma. Blood, 2017, 130, 738-738.	1.4	5
108	An integrated approach to cardioprotection in lymphomas. Lancet Haematology,the, 2022, 9, e445-e454.	4.6	5

#	Article	IF	Citations
109	Ethnic differences in chronic health conditions after hematopoietic cell transplantation. Cancer, 2010, 116, 4152-4159.	4.1	4
110	Aging in a Relativistic Biological Space-Time. Frontiers in Cell and Developmental Biology, 2018, 6, 55.	3.7	4
111	High prevalence and inferior longâ€term outcomes for <scp>TP53</scp> mutations in therapyâ€related acute lymphoblastic leukemia. American Journal of Hematology, 2022, 97, .	4.1	4
112	Long-Term Follow-Up of Multiple Myeloma Patients Treated with Tandem Autologous Transplantation Following Melphalan and Upon Recovery, Total Marrow Irradiation. Transplantation and Cellular Therapy, 2022, 28, 367.e1-367.e9.	1.2	4
113	Screening for Anthracycline-Related Cardiac Dysfunction in Childhood Cancer Survivors: Can Less be More?. Pediatric Blood and Cancer, 2015, 62, 2067-2068.	1.5	3
114	Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report. Cancer, 2019, 125, 4033-4042.	4.1	3
115	Late Mortality after Allogeneic Bone Marrow Transplantation in Childhood for Bone Marrow Failure Syndromes and Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2019, 25, 749-755.	2.0	3
116	Reactivation of human herpesvirus 6 in pediatric allogeneic hematopoietic stem cell transplant recipients. Transplant Infectious Disease, 2021, 23, e13453.	1.7	3
117	EfficacyÂofÂtheÂChildren's Oncology GroupÂ(COG)Âlong-term follow-upÂ(LTFU)ÂguidelinesÂinÂreducing riskÂofÂcongestive heart failureÂ(CHF)ÂinÂchildhood cancer survivorsÂ(CCS).. Journal of Clinical Oncology, 2012, 30, 9505-9505.	1.6	3
118	Conditioning intensity and probability of live birth after blood or marrow transplantation, a BMTSS report. Blood Advances, 2022, 6, 2471-2479.	5.2	3
119	Association Between Body Composition and Development of Glucose Intolerance after Allogeneic Hematopoietic Cell Transplantation. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 2004-2010.	2.5	3
120	Improving Screening Practices in Childhood Cancer Survivors at Risk for Treatment-Related Heart Failure. Journal of Clinical Oncology, 2014, 32, 3923-3925.	1.6	2
121	Health equity for displaced children with cancer in the Middle East. Cancer, 2018, 124, 1322-1325.	4.1	2
122	Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2. Leukemia, 2018, 32, 2706-2709.	7.2	2
123	Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes. Blood Cancer Journal, 2021, 11, 125.	6.2	2
124	Reduction in Late Mortality Among Patients With Multiple Myeloma Treated With Autologous Peripheral Blood Stem Cell Transplantationâ€"A Blood or Marrow Transplant Survivor Study Report. Transplantation and Cellular Therapy, 2021, 27, 840.e1-840.e7.	1.2	2
125	Persistent Musculoskeletal Deficits in Pediatric, Adolescent and Young Adult Survivors of Allogeneic Hematopoietic Stem-Cell Transplantation. Journal of Bone and Mineral Research, 2020, 37, 794-803.	2.8	2
126	Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation. Leukemia and Lymphoma, 2022, 63, 1220-1226.	1.3	2

#	Article	IF	Citations
127	Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls.. Journal of Clinical Oncology, 2022, 40, 12042-12042.	1.6	2
128	Neighborhood disadvantage, health status, and health care utilization after blood or marrow transplant: BMTSS report. Blood Advances, 2023, 7, 293-301.	5.2	2
129	Clinical heart failure in children, adolescents and young adults treated with anthracyclines and/or irradiation involving the heart region. The Cochrane Library, 0, , .	2.8	1
130	Screening and intervention for treatment-related cardiac dysfunction in childhood cancer survivors. Future Oncology, 2015, 11, 2031-2034.	2.4	1
131	A pediatric-type follicular lymphoma with marginal zone and monotypic intracytoplasmic plasmacytic differentiation. Human Pathology: Case Reports, 2018, 11, 25-31.	0.2	1
132	Technology-enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers (TEACH). BMC Cancer, 2020, 20, 721.	2.6	1
133	Atlas-based measures of left ventricular shape may improve characterization of adverse remodeling in anthracycline-exposed childhood cancer survivors: a cross-sectional imaging study. Cardio-Oncology, 2020, 6, 13.	1.7	1
134	Feasibility of geriatric assessment before transplant conditioning regimen in older HCT recipients. Bone Marrow Transplantation, 2021, 56, 726-729.	2.4	1
135	Incidence and Risk Factors for De Novo Cutaneous Squamous Cell Carcinoma in a Contemporary Cohort of Long-Term Hematopoietic Cell Transplantation Survivors. Journal of Investigative Dermatology, 2021, 141, 2073-2076.e5.	0.7	1
136	Southern California Pediatric and Adolescent Cancer Survivorship (SC-PACS): Establishing a Multi-Institutional Childhood, Adolescent, and Young Adult Cancer Survivorship Consortium in Southern California. Cureus, 2022, 14, e21981.	0.5	1
137	Differential Morbidity by Ethnicity in Long-Term Survivors of Hematopoietic Cell Transplantation (HCT): A Report from the Bone Marrow Transplant Survivor Study (BMTSS). Blood, 2008, 112, 454-454.	1.4	0
138	Late Cardiovascular Events in Survivors of Hematopoietic Cell Transplantation (HCT).. Blood, 2009, 114, 2252-2252.	1.4	0
139	CELF4 variant and Anthracycline-related Cardiomyopathy (anth-card) â€“ A COG Study (ALTE03N1).. Journal of Clinical Oncology, 2015, 33, 10066-10066.	1.6	0
140	Decline in Late Mortality after Allogeneic Blood or Marrow Transplantation (alloBMT) Performed in Childhood: a Report from the BMT Survivor Study-2 (BMTSS-2). Blood, 2017, 130, 672-672.	1.4	0
141	Burden of Morbidity after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism: A BMT Survivor Study Report. Transplantation and Cellular Therapy, 2022, 28, 157.e1-157.e9.	1.2	0
142	Leveraging clinical trial populations and data from the Children's Oncology Group for cancer survivorship research. Cancer Epidemiology Biomarkers and Prevention, 0, , .	2.5	0